A Vancouver-based biotech company called Symvivo Corporation recently launched a Phase I clinical trial to asses the safety of a COVID-19 vaccine biological candidate known as bacTRL-Spike. A Bifidobacteria monovalent SARS-CoV-2 DNA oral vaccine candidate to prevent...